TScan Shares Jump 23% on Securities Purchase Agreement

Dow Jones
2024-12-26
 

By Denny Jacob

 

TScan Therapeutics shares jumped 23% in premarket trading after a $30 million registered direct offering.

Shares were trading around $3.58. The stock is down about 50% on the year.

The Waltham, Mass.-based clinical-stage biotechnology company said it entered into a securities purchase agreement with Lynx1 Capital Management and investment fund advised by Lynx1 for the sale of about $30 million of pre-funded warrants to purchase up to an aggregate of 7.5 million shares of its voting common stock at a price of $4 per pre-funded warrant.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

December 26, 2024 09:13 ET (14:13 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10